Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $700.00 at Bernstein Bank

Intuitive Surgical (NASDAQ:ISRG) had its price target boosted by Bernstein Bank from $655.00 to $700.00 in a research report report published on Monday, Marketbeat Ratings reports. They currently have an overweight rating on the medical equipment provider’s stock.

ISRG has been the topic of several other research reports. Citigroup lifted their target price on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Mizuho upped their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Leerink Partners raised their price target on shares of Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Barclays increased their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday. Finally, Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Performance

ISRG stock opened at $572.71 on Monday. The business has a 50-day simple moving average of $548.70 and a two-hundred day simple moving average of $507.04. The company has a market capitalization of $203.99 billion, a P/E ratio of 92.08, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. Intuitive Surgical has a 52-week low of $364.17 and a 52-week high of $616.00.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares in the company, valued at $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,967,734. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,843 shares of company stock valued at $15,357,560 over the last quarter. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Institutional investors and hedge funds have recently bought and sold shares of the company. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth $26,000. Godsey & Gibb Inc. grew its position in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical in the 3rd quarter worth about $33,000. Decker Retirement Planning Inc. purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $36,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Intuitive Surgical during the 3rd quarter valued at about $38,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.